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ABSTRACT
We tested the hypothesis that phosphodiesterase type 5
inhibitor (PDE5i) use would be associated with increased
likelihood of condom breakage using an event-specific
analysis.
A convenience sample of 440 men completed an internet-
based questionnaire that assessed variables pertaining to
the last time they used condoms for penile-vaginal
intercourse (PVI). A bivariate (screening) analysis was
performed to identify covariates for a multivariate analysis
using logistic regression.
Altogether, 5.9% of the men reported breakage and 9.5%
reported PDE5i use during the last time a condom was
used for PVI. Among men who had used PDE5i during the
last condom-protected occasion of PVI, 11.9% reported
breakage compared with 5.3% of those not reporting
PDE5i use. Adjusting for men’s age, ethnic minority
status, marital status, reported duration of PVI and alcohol
use at last PVI, those using PDE5i were about four times
more likely to also report condom breakage (AOR 4.02;
95% CI 1.20 to 13.48; p = 0.04). Of note, duration of PVI
was independently associated with breakage (AOR 1.36;
CI 1.02 to 1.83; p = 0.04).
Findings suggest that PDE5i use may potentially be
associated with increased odds of condom breakage
among some men.
Phosphodiesterase type 5 inhibitor (PDE5i) drugs
have been widely used as a treatment for erectile
dysfunction.1 Although generally regarded as effec-
tive and safe, these drugs have also been associated
with increased rates of high-risk sexual behaviour
and HIV transmission in some men.2 Whether
PDE5i increase the odds of condom breakage has
not been studied. Breakage is not uncommon and
largely negates the protective value of condoms
relative to the prevention of pregnancy or sexually
transmitted infections.3–5 Given the enhanced
erections provided by PDE5i, it is plausible that
condoms become more tight-fitting. Tight-fitting
condoms have been associated with breakage.6–9
METHODS
Study sample
A convenience sample (n = 440) was recruited via
advertisements in newspapers (two urban and one
small town) and a blog on the website of a condom
sales company that directed men to the question-
naire that was posted on the website of The Kinsey
Institute. Inclusion criteria were male, at least 18
years old, used condoms for penile-vaginal inter-
course (PVI) in the past 3 months and the ability to
read English.
Measures
Assessments focused on the last condom use event
for PVI. Condom breakage, PDE5i use and three
covariates—duration of PVI, degree of vaginal
lubrication and alcohol use (previously shown to
be related to condom breakage9)—were assessed by
asking the following questions, respectively:
Thinking about the last time you used a condom
for PVI…
Q1. Did the condom break during PVI? (no, yes,
I don’t know)
Q2. Did you use Viagra, Cialis or Levitra? (no,
yes)
Q3. How long was your penis in the vagina?
(less than a minute, 1–5, 6–10, 11–15, 16–20, 21 or
more minutes)
Q4. How well lubricated was your partner’s
vagina? (very well lubricated (moist and slippery),
adequate lubrication (no dry feeling), not quite
enough lubrication (a little dry), poorly lubricated
(very dry))
Q5. Were you drinking alcoholic beverages? (no,
1–2, 3–5, more than 5 drinks; a drink equals 1 beer,
glass of wine or shot of liquor)
Data analysis
Continuous covariates not meeting normality
assumptions were dichotomised by a median split.
Variables achieving a screening-level of bivariate
significance (p,0.15) with condom breakage or
PDE5i use were entered into a multiple logistic
regression model to calculate adjusted odds ratios
(AOR), their 95% confidence intervals (CIs) and
respective p values.
RESULTS
Characteristics of the sample
Average age was 29.6 years (SD 10.1). Breakage
was reported by 26 men (5.9%) and 42 men (9.5%)
reported PDE 5i use. Table 1 shows descriptive
information relative to the dichotomised measures.
Bivariate associations
PDE5i use, alcohol use and minority ethnicity
achieved screening significance (table 1). Table 1
displays the number of men responding ‘‘yes vs
no’’ for each variable as well as the percentage of
that number who reported condom breakage. For
example, 42 reported PDE5i use and 11.9% of these
(n = 5) also reported breakage compared with 5.3%
(n = 21) of the 398 men not using PDE5i. Men’s
age and reported duration of PVI were preserved as
continuous-level variables; therefore, bivariate
associations were based on independent group t
tests. Age did not vary between men reporting
breakage (mean age = 28.1 years) and not reporting
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breakage (mean age = 29.7 years) (t = 0.78 (438); p = 0.43).
However, duration of PVI score was significantly longer among
those reporting breakage (mean score = 4.7) versus those not
reporting breakage (mean score = 4.0; t = 2.45 (438); p = 0.015).
PDE5i users were significantly older (mean age 41.1 years)
than non-users (28.4 years; t = 8.3 (438); p,0.0001). PDE5i use
was significantly more common among married men (18.5%)
than single men (5.6%; p,0.001).
Multivariate associations
The logistic regression model using age, minority status (no/
yes), single (no/yes), duration (scale 1 (less than 1 minute) to 6
(21 or more minutes)), alcohol use (no/yes) and PDE5i use (no/
yes) was significant (x2 with 6df = 16.01; p = 0.01) and
produced a satisfactory fit with the data (goodness of fit x2
with 8df = 9.45; p = 0.31). Minority ethnicity (AOR 2.59; 95%
CI 1.04 to 6.43; p = 0.04), duration of PVI (AOR 1.36; 95% CI
1.02 to 1.83; p = 0.04) and PDE5i use (AOR 4.04; 95% CI 1.06 to
15.41; p = 0.04) achieved multivariate significance.
DISCUSSION
In a controlled analysis, condom breakage was about four times
more likely among men using PDE5i drugs. However, a previous
study of an older sample found that some men still experience
erection problems while trying to use condoms in spite of PDE
5i use.10 Such findings highlight the importance of further
studies, including qualitative research, to examine implications
for physicians prescribing PDE5i drugs.
Findings are limited by the validity of retrospective self-report
and the use of a convenience sample. Although the use of event-
specific analysis adds considerable strength to the study, this
feature precludes the use of a repeated measures design that
would allow for within-person comparisons as a function of
PDE5i use. Given support from further investigations regarding
PDE5i use and condom breakage, counselling could emphasise
the following messages: 1) use condoms large enough to fit the
enhanced erections that may be experienced and 2) understand
that longer duration of intercourse may be associated with
increased risk of breakage. Because not all PDE5i use is through
prescription,2 these same implications may also be relevant in
sexually transmitted infections clinics.
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Commentary
The article by Crosby and colleagues1 in the current edition of
the journal suggests that the use of phosphodiesterase 5
inhibitors (PDE5i) (sildenafil, tadalafil and vardenafil) by men
is associated with a significantly increased rate of condom
breakage compared with men who use condoms but not PDE5i.
This seems biologically plausible in that whatever the degree of
a man’s natural penile rigidity, PDE5i use can enhance that
intensity of tumescence.2
The use of PDE5i in HIV and other sexually transmitted
infection (STI) acquisition and transmission is of importance,
particularly in men who have sex with men (MSM). In clinical
Table 1 Bivariate associations between dichotomous measures and
condom breakage
% break* PR{ (95% CI{) p Value
Minority ethnicity
No (n = 371) 4.9 2.39 (1.08 to 5.28) 0.029
Yes (69) 11.6
Single
No (135) 6.2 1.20 (0.52 to 2.79) 0.67
Yes (305) 5.2
Used erection enhancing
drugs1
Yes (42) 11.9 2.25 (0.90 to 5.67) 0.08
No (398) 5.3
Partner’s vagina well
lubricated1
No (190) 6.3 1.12 (0.58 to 2.38) 0.75
Yes (250) 5.6
Used alcohol1
No (249) 7.9 1.78 (0.84 to 3.78) 0.13
Yes (191) 4.4
*Defined as experiencing breakage the time a condom was used for penile-vaginal
sex; {prevalence ratio; {confidence interval; 1pertaining to the last time a condom
was used for penile-vaginal intercourse.
Key messages
c Phosphodiesterase type 5 inhibitor (PDE5i) use may be a risk
factor for condom breakage.
c Given further support for the hypothesis that PDE5i use is a
risk factor for condom breakage, counselling messages to men
being prescribed these drugs may need to include objectives
designed to avert breakage.
c Men attending sexually transmitted infections clinics and
reporting PDE5i use may also benefit from counselling
designed to reduce their risk of condom breakage.
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